That’s why timely screening should be part of your regular health check-upPurdue University’s Center for Healthy Living (CHL), in conjunction with Cologuard® and Exact Sciences, is providing no-cost, ...

Multitarget stool DNA test (Cologuard) This combines testing for ... finding small amounts of blood in your poop are based on the fact that blood vessels on large polyps and cancers are easily ...

If you would like to create a fact sheet for your unit, school, department or program, refer to the following resources and contact your senior communicator. Please note: the school sample below is ...

Ask your doctor whether Cologuard is a good option for you instead of or before considering a colonoscopy. Learn more about cancer screening and Medicare. The information on this website may ...

Fact checked by Nick Blackmer A blood test is now available to screen for colorectal cancer.However, a recent study concluded ...

The blood is tested for biomarkers and DNA mutations that are present with cancer. Another option, Cologuard, can be done at home — you collect a sample of your stool and mail it to a lab with ...

Exact Sciences rose Friday after the Food and Drug Administration approved its next-generation colon cancer detection test, ...

Cologuard Plus™ test raises the performance bar with sensitivities of 95% for colorectal cancer and 43% for advanced precancerous lesions at 94% specificity Cologuard Plus test will minimize ...

Exact Sciences shares plunged Wednesday after the company reported widening losses. The maker of the Cologuard colon cancer screening test lowered its full-year outlook. CEO Kevin Conroy said the ...

Which well-being indicators are relevant to the Ministry’s budget and policy agenda? The Fact Sheets provide an insight into the status quo regarding well-being in the policy areas of the Ministry, ...

The UAB-SCIMS offers a series of Fact Sheets on selected topics related to SCI. Some Fact Sheets are products of the University of Alabama at Birmingham Spinal Cord Injury Model System (UAB-SCIMS).

The maker of the Cologuard colon cancer screening test lowered its full-year outlook. CEO Kevin Conroy said the firm's quarterly execution and forecast don't reflect its full potential.